Patent · US Active

Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue

US10040840B2 · kind B2 · utility

5Cited by

15References

20Claims

0Family size

Assignee

Silver Creek Pharmaceuticals, Inc. · US

Inventors

Laura D.J. Antipov · Oakland, US
Shawdee Eshghi · Oakland, US
Kristopher M. Kuchenbecker · San Francisco, US
Bjorn L. Millard · Orinda, US
Matthew Onsum · Corona, US
Andrea D. Nickerson · San Francisco, US
Timothy R. Stowe · San Francisco, US
Yan Zhang · San Francisco, US

Key dates

Filing date	Sep 30, 2016
Grant date	Aug 7, 2018
Priority date	—
Expiry date	Sep 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.